Fluff Or Next Potential Discovery? FDA Wants Simpler Clinical Trials, But Not Telling Sponsors Endpoints Are Unnecessary
Executive Summary
Some of the growing number of secondary and tertiary endpoints may not be needed, but also could fuel future products and advance science.